BRAFV600E: implications for carcinogenesis and molecular therapy.
AffiliationDepartment of Histopathology, Trinity College, Sir Patrick Dun Research, Laboratory, Pathology Building, St. James' Hospital, Dublin 8, Ireland., firstname.lastname@example.org
Cell Transformation, Neoplastic/*genetics
Extracellular Signal-Regulated MAP Kinases/genetics/metabolism
Mitogen-Activated Protein Kinases/*genetics/metabolism
*Molecular Targeted Therapy
Proto-Oncogene Proteins B-raf/*genetics
MetadataShow full item record
CitationMol Cancer Ther. 2011 Mar;10(3):385-94.
JournalMolecular cancer therapeutics
AbstractThe mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer. This pathway consists of a small GTP protein of the RAS family that is activated in response to extracellular signaling to recruit a member of the RAF kinase family to the cell membrane. Active RAF signals through MAP/ERK kinase to activate ERK and its downstream effectors to regulate a wide range of biological activities including cell differentiation, proliferation, senescence, and survival. Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) isoform of the RAF kinase or KRAS isoform of the RAS protein are found as activating mutations in approximately 30% of all human cancers. The BRAF pathway has become a target of interest for molecular therapy, with promising results emerging from clinical trials. Here, the role of the most common BRAF mutation BRAF(V600E) in human carcinogenesis is investigated through a review of the literature, with specific focus on its role in melanoma, colorectal, and thyroid cancers and its potential as a therapeutic target.
- Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
- Authors: Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Matsumura M, Kawabe T, Omata M
- Issue date: 2004 May 15
- Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
- Authors: Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N
- Issue date: 2007 Mar
- Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
- Authors: Tran G, Huynh TN, Paller AS
- Issue date: 2018 Mar
- Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
- Authors: Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M
- Issue date: 2009 Apr 1
- Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
- Authors: Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M
- Issue date: 2011 Jan